Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Musculoskeletal | Neurology | Family Medicine
Search Medical Condition
Multiple Sclerosis Clinical Trials
A listing of Multiple Sclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (441) clinical trials
Randomized Comparison of the Clinical Outcome of Single versus Multiple Arterial Grafts: the ROMA Trial
The study objective is to determine if the use of two or more arterial grafts in coronary artery bypass surgery (CABG) compared to a single arterial graft is associated with improved survival. There is no "experimental" procedures being tested in this study. Cardiac surgeons use both arterial and vein grafts ...
A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis
Primary Objective: - To determine the efficacy of SAR442168 in reducing the number of new brain lesions reported in Magnetic Resonance Imaging (MRI) Secondary Objectives: - To evaluate the efficacy of SAR442168 on clinical symptoms and imaging measures - To evaluate the safety and tolerability of SAR442168
An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients with Generalized Myasthenia Gravis IND 140,115 STUDY NUMBER: ALXN1210-MG-306
Primary To assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on the improvement in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) profile. Secondary To assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on the improvement in the Quantitative ...
AnaLysIs of Both Sex and Device Specific FactoRs on Outcomes in PAtients with Non-Ischemic Cardiomyopathy - Bio Libra
Secondary Objectives All-cause mortality, VT or VF alone, risk of cardiac death, and sudden cardiac death for the total cohort, as well as by sex and by the implanted device type. Compare the predicted incidence of sudden death using the Seattle Proportional Risk score to the observed incidence in this ...
CLadribine tablets: Observational evaluation of effectIveness and patient-reported outcomes (PROs) in suboptimally Controlled patients previously taKing injectable disease-modifying drugs (DMDs) for relapsing forms of Multiple Sclerosis (RMS) (CLICK-MS)
Primary Objective: To estimate the annualized relapse rate (ARR) over a 24-month period in patients with RMS who are treated with cladribine tablets in a real-world setting and after suboptimal response to any injectable DMD approved in the US for RMS Secondary Objectives: To assess PROs and treatment adherence during ...
Cladribine tablets: Observational evaluation of effectiveness and patient-reported outcomes (PROs) in suboptiMAlly controlled patientS previously Taking oral disEase-modifying dRugs (DMDs) for relapsing forms of multiple sclerosis (RMS) (MASTER-2)
Primary Objective: To estimate the annualized relapse rate (ARR) over a 24-month period in patients with RMS who are treated with cladribine tablets in a real-world setting and after suboptimal response to any oral DMD approved in the US for RMS Secondary Objectives: To assess PROs and treatment adherence during ...
Exploring the safety and tolerability of conversion to dose-titrated Oral Siponimod in patients with advancing forms of relapsing multiple sclerosis: A 6-month open label, multi-center Phase IIIb study (EXCHANGE) Protocol Number: CBAF312AUS02
The purpose of the study is to see how safe it is and how well you tolerate changing the MS medicine you are taking currently for your MS to siponimod (an investigational drug for MS). The results of this study will help doctors decide if and when to switch patients ...
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis PASS – OBS13434
The proposed study utilizes a prospective, non-interventional, observational cohort study design to evaluate the necessary duration of monitoring following treatment with LEMTRADA and to further inform appropriate monitoring conditions. It will evaluate the long term safety profile, particularly the AESI incidence rates over time in RMS patients, to accomplish the ...
A Prospective, 24-Month Observational Study to Evaluate Patient Reported Outcomes and Safety After LEMTRADA® Treatment In Patients With Relapsing Multiple Sclerosis Switching From A Prior Disease Modifying Therapy
6.1 PRIMARY The primary objective of the study is to evaluate treatment satisfaction as the primary Patient- Reported Outcome (PRO) in patients with relapsing forms of MS (RMS) treated with LEMTRADA in a real life setting using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4. 6.2 SECONDARY The secondary ...
